3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
11
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Head and Neck Neoplasms
7
Neoplasms
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Hypoparathyroidism
2
Carcinoma, Squamous Cell
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Diseases
1
Recurrence
1
Rectal Neoplasms
1
Parathyroid Diseases
1
Ovarian Neoplasms
1
Neovascularization, Pathologic
1
Melanoma
1
Margins of Excision
1
Lymphedema
1
Head and Neck Carcinoma
1
Graves Disease
1
Goiter
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Adenoma
1
Interventions
pembrolizumab
19
Paclitaxel
6
Trastuzumab
5
Nivolumab
5
palbociclib
4
Carboplatin
4
Biopsy
4
lenvatinib
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Immunoglobulin G
3
Fulvestrant
3
Cyclophosphamide
3
Cetuximab
3
trastuzumab deruxtecan
2
tisotumab vedotin
2
spartalizumab
2
sargramostim
2
gedatolisib
2
fludarabine
2
epacadostat
2
capivasertib
2
X-Rays
2
Sunitinib
2
Docetaxel
2
Disulfides
2
Cisplatin
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Indocyanine Green
×
Head & Neck
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled